Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy

Key Points

• To evaluate the effectiveness of amivantamab in patients with non-small cell lung cancer who have EGFR exon 20 mutations after platinum-based chemotherapy.
• Compared amivantamab with current real-world therapies
• Analyzed outcomes from the CHRYSALIS trial
• Focused on patients with EGFR ex20ins mutations
• Amivantamab shows improved effectiveness compared to real-world therapies
• Addresses the urgent need for treatment options in a specific patient population
• Highlights the potential of amivantamab as a promising alternative post-chemotherapy